Steven Cohen Vir Biotechnology, Inc. Transaction History
Point72 Asset Management, L.P.
- $39.3 Billion
- Q1 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 32,500 shares of VIR stock, worth $277,225. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,500
Previous 8,000
306.25%
Holding current value
$277,225
Previous $80,000
311.25%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding VIR
# of Institutions
225Shares Held
88.2MCall Options Held
177KPut Options Held
182K-
Sb Investment Advisers (Uk) LTD London, X016.7MShares$142 Million1.67% of portfolio
-
Black Rock Inc. New York, NY16.6MShares$141 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.4MShares$106 Million0.0% of portfolio
-
State Street Corp Boston, MA7.07MShares$60.3 Million0.0% of portfolio
-
Baillie Gifford & CO3.95MShares$33.7 Million0.03% of portfolio
About Vir Biotechnology, Inc.
- Ticker VIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 132,638,000
- Market Cap $1.13B
- Description
- Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...